Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Starts Presentation at 30th Annual ROTH Conference
Madrigal Pharmaceuticals (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal’s lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist that is currently in Phase 2 development for non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). For more information, visit the company’s website at www.madrigalpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides…







